| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
Rewards
Risk Analysis
No risks detected for 600161 from our risk checks.
Beijing Tiantan Biological Products Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥28.34 |
| 52 Week High | CN¥32.73 |
| 52 Week Low | CN¥23.00 |
| Beta | 0.28 |
| 1 Month Change | -1.49% |
| 3 Month Change | 1.72% |
| 1 Year Change | 8.37% |
| 3 Year Change | 4.38% |
| 5 Year Change | 92.50% |
| Change since IPO | 1,282.57% |
Recent News & Updates
Recent updates
Shareholder Returns
| 600161 | CN Biotechs | CN Market | |
|---|---|---|---|
| 7D | -0.6% | -0.1% | -0.4% |
| 1Y | 8.4% | -19.9% | -12.6% |
Return vs Industry: 600161 exceeded the CN Biotechs industry which returned -19.9% over the past year.
Return vs Market: 600161 exceeded the CN Market which returned -12.6% over the past year.
Price Volatility
| 600161 volatility | |
|---|---|
| 600161 Average Weekly Movement | 4.3% |
| Biotechs Industry Average Movement | 6.1% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in CN Market | 10.0% |
| 10% least volatile stocks in CN Market | 4.1% |
Stable Share Price: 600161 has not had significant price volatility in the past 3 months.
Volatility Over Time: 600161's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1919 | 4,858 | Dao Xing Fu | www.tiantanbio.com |
Beijing Tiantan Biological Products Co., Ltd. engages in the research and development, manufacture, sale, and consulting of blood products in China. Its products include human albumin; intravenous human immunoglobulin; tetanus human immunoglobulin; rabies patient immunoglobulin; hepatitis B human immunoglobulin; freeze-dried intravenous hepatitis B human immunoglobulin; and human prothrombin complex blood products.
Beijing Tiantan Biological Products Co., Ltd. Fundamentals Summary
| 600161 fundamental statistics | |
|---|---|
| Market cap | CN¥46.70b |
| Earnings (TTM) | CN¥1.16b |
| Revenue (TTM) | CN¥5.11b |
40.1x
P/E Ratio9.1x
P/S RatioIs 600161 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 600161 income statement (TTM) | |
|---|---|
| Revenue | CN¥5.11b |
| Cost of Revenue | CN¥2.39b |
| Gross Profit | CN¥2.72b |
| Other Expenses | CN¥1.55b |
| Earnings | CN¥1.16b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.71 |
| Gross Margin | 53.20% |
| Net Profit Margin | 22.79% |
| Debt/Equity Ratio | 0% |
How did 600161 perform over the long term?
See historical performance and comparison